Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P32189
UPID:
GLPK_HUMAN
Alternative names:
ATP:glycerol 3-phosphotransferase
Alternative UPACC:
P32189; A6NJP5; B2R833; Q6IQ27; Q8IVR5; Q9UMP0; Q9UMP1
Background:
Glycerol kinase, encoded by the gene with accession number P32189, plays a pivotal role as a key enzyme in the regulation of glycerol uptake and metabolism. Known alternatively as ATP:glycerol 3-phosphotransferase, this protein is essential for the proper handling of glycerol within the cell, facilitating its conversion into a form that can be readily utilized in metabolic pathways.
Therapeutic significance:
Glycerol kinase deficiency (GKD) manifests in various forms, from severe developmental delay and adrenal insufficiency in its infantile form to asymptomatic adult cases. Understanding the role of Glycerol kinase could open doors to potential therapeutic strategies, offering hope for targeted interventions in metabolic disorders like GKD.